Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models-Reference-Cited by-同舟云学术

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

Published:2016-10-13 Issue:11 Volume:5 Page:3176-3185
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Zopf Dieter¹,Fichtner Iduna²,Bhargava Ajay³,Steinke Wolfram⁴,Thierauch Karl‐Heinz¹,Diefenbach Konstanze¹,Wilhelm Scott⁵,Hafner Frank‐Thorsten¹,Gerisch Michael¹

Affiliation:

1. Drug Discovery Bayer Pharma AG Müllerstraße 178 Berlin 13353 Germany

2. Experimental Pharmacology & Oncology GmbH Robert‐Rössle‐Str. 10 Berlin‐Buch 13125 Germany

3. Shakti Bioresearch 1 Bradley Road, STE 401 Woodbridge Connecticut 06525

4. Pharmacokinetic Imaging Consulting & Autoradiography Services Halverscheid 13, D‐58553 Halver Germany

5. Bayer HealthCare Pharmaceuticals 100 Bayer Blvd Whippany New Jersey 07981

Funder

Bayer

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.883

Reference23 articles.

1. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

2. Regorafenib for cancer

3. The preclinical development of regorafenib for the treatment of colorectal cancer

4. A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

5. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Intraperitoneal Chemotherapy with Regorafenib on IL-6 and TNF-α Levels and Peritoneal Cytology: Experimental Study in Rats with Colorectal Peritoneal Carcinomatosis;Journal of Clinical Medicine;2023-11-23

2. Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview;Expert Opinion on Drug Metabolism & Toxicology;2023-10-20

3. Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis;British Journal of Cancer;2023-08-24

4. Evaluating the Pharmacokinetics and Pharmacodynamics of Chemotherapeutics within a Spatial SILAC-Labeled Spheroid Model System;Analytical Chemistry;2023-07-18

5. Decoding the Mechanism of Drugs of Heterocyclic Nature against Hepatocellular Carcinoma;Anti-Cancer Agents in Medicinal Chemistry;2023-05